Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 3
2011 2
2012 5
2013 7
2014 12
2015 7
2016 6
2017 7
2018 5
2019 6
2020 11
2021 9
2022 3
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4.
Ghose A, McCann L, Makker S, Mukherjee U, Gullapalli SVN, Erekkath J, Shih S, Mahajan I, Sanchez E, Uccello M, Moschetta M, Adeleke S, Boussios S. Ghose A, et al. Among authors: moschetta m. Ther Adv Med Oncol. 2024 Feb 29;16:17588359241233225. doi: 10.1177/17588359241233225. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38435431 Free PMC article. Review.
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Janku F, Kim TM, Iyer G, Spreafico A, Elez E, de Jonge M, Yamamoto N, van der Wekken AJ, Ascierto PA, Maur M, Marmé F, Kiladjian JJ, Basu S, Baffert F, Buigues A, Chen C, Cooke V, Giorgetti E, Kim J, McCarthy F, Moschetta M, Dummer R. Janku F, et al. Among authors: moschetta m. Eur J Cancer. 2024 Jan;196:113458. doi: 10.1016/j.ejca.2023.113458. Epub 2023 Nov 21. Eur J Cancer. 2024. PMID: 38039779 Clinical Trial.
Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer-A Retrospective UK Single-Centre Study.
Vassiliou A, Osunronbi T, Enyioma S, Rago G, Karathanasi A, Ghose A, Sheriff M, Mikropoulos C, Sanchez E, Moschetta M, Chargari C, Rassy E, Boussios S. Vassiliou A, et al. Among authors: moschetta m. Cancers (Basel). 2023 Sep 6;15(18):4432. doi: 10.3390/cancers15184432. Cancers (Basel). 2023. PMID: 37760402 Free PMC article.
Melanoma-the therapeutic considerations in the clinical practice.
Adeleke S, Okoli S, Augustine A, Galante J, Agnihotri A, Uccello M, Ghose A, Moschetta M, Boussios S. Adeleke S, et al. Among authors: moschetta m. Ann Palliat Med. 2023 Nov;12(6):1355-1372. doi: 10.21037/apm-22-1432. Epub 2023 Jun 30. Ann Palliat Med. 2023. PMID: 37431221 Free article.
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development.
Dickinson MJ, Barba P, Jäger U, Shah NN, Blaise D, Briones J, Shune L, Boissel N, Bondanza A, Mariconti L, Marchal AL, Quinn DS, Yang J, Price A, Sohoni A, Treanor LM, Orlando EJ, Mataraza J, Davis J, Lu D, Zhu X, Engels B, Moutouh-de Parseval L, Brogdon JL, Moschetta M, Flinn IW. Dickinson MJ, et al. Among authors: moschetta m. Cancer Discov. 2023 Sep 6;13(9):1982-1997. doi: 10.1158/2159-8290.CD-22-1276. Cancer Discov. 2023. PMID: 37249512 Free PMC article.
A View on Drug Development for Cancer Prevention.
Reynolds AR, Moschetta M, Yohannes AR, Walcott F, Ashford M, Szucs Z, Sarbajna T, Hadfield J, Harrison E, Challis BG, Hernandez AG, Schiavon G, Germa C, Zorenyi G, Crean B, Galbraith S. Reynolds AR, et al. Among authors: moschetta m. Cancer Discov. 2023 May 4;13(5):1058-1083. doi: 10.1158/2159-8290.CD-22-0776. Cancer Discov. 2023. PMID: 37067191 Review.
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
de Braud F, Dooms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D, Rutkowski P, Wolf J, Ascierto PA, Gil-Bazo I, Kato S, Wolodarski M, McKean M, Muñoz Couselo E, Sebastian M, Santoro A, Cooke V, Manganelli L, Wan K, Gaur A, Kim J, Caponigro G, Couillebault XM, Evans H, Campbell CD, Basu S, Moschetta M, Daud A. de Braud F, et al. Among authors: moschetta m. J Clin Oncol. 2023 May 10;41(14):2651-2660. doi: 10.1200/JCO.22.02018. Epub 2023 Mar 22. J Clin Oncol. 2023. PMID: 36947734 Clinical Trial.
Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors.
Aliyuda F, Moschetta M, Ghose A, Sofia Rallis K, Sheriff M, Sanchez E, Rassy E, Boussios S. Aliyuda F, et al. Among authors: moschetta m. Curr Cancer Drug Targets. 2023;23(6):433-446. doi: 10.2174/1568009623666230209121732. Curr Cancer Drug Targets. 2023. PMID: 36757037
86 results